KIORA PHARMACEUTICALS INC current report, 26 February 2018

Business Context and Reporting Period

Company: EyeGate Pharmaceuticals, Inc. (Note: Request metadata listed "Kiora Pharmaceuticals Inc," but the filing text identifies the registrant as EyeGate Pharmaceuticals, Inc.)
Filing Type: Form 8-K (Current Report)
Date: February 26, 2018
Context: The filing serves as a Regulation FD disclosure to furnish a presentation (Exhibit 99.1) scheduled for the 2018 Winter Symposium of the American-European Congress of Ophthalmic Surgery in Aspen, Colorado. The presentation is to be delivered by Michael Raizman, MD, a member of the Company's Scientific Advisory Board.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to disclose a presentation and does not contain financial statements or quantitative financial data.

Material Changes

No material changes to financial performance or operations are reported in this filing. The document solely announces the furnishing of a presentation regarding the Company's activities.

Guidance, Outlook, and Risks

  • Management Commentary: The Company explicitly states that the information furnished, including the attached presentation, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.
  • Forward-Looking Statements: The Company does not assume any obligation to update the information or exhibit in the future.
  • Regulatory Status: The registrant is identified as an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.

Investor Verification Checklist

  • Verify the content of Exhibit 99.1 (the presentation) for specific clinical data or strategic updates, as the 8-K text itself contains no operational details.
  • Confirm the distinction between the registrant name in the filing (EyeGate Pharmaceuticals, Inc.) and the name in the request metadata (Kiora Pharmaceuticals Inc).
  • Note that the Company has disclaimed any obligation to update the information provided in the presentation.